- Home
- HSCS vs SONN Comparison
HSCS vs SONN Comparison
Compare HSCS & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- SONN
- Stock Information
- Founded
- HSCS 2007
- SONN N/A
- Country
- HSCS United States
- SONN United States
- Employees
- HSCS N/A
- SONN N/A
- Industry
- HSCS Medical Specialities
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- HSCS Health Care
- SONN Health Care
- Exchange
- HSCS Nasdaq
- SONN Nasdaq
- Market Cap
- HSCS 3.7M
- SONN 3.8M
- IPO Year
- HSCS 2022
- SONN N/A
- Fundamental
- Price
- HSCS $3.57
- SONN $4.14
- Analyst Decision
- HSCS Strong Buy
- SONN Strong Buy
- Analyst Count
- HSCS 2
- SONN 1
- Target Price
- HSCS $13.00
- SONN $20.00
- AVG Volume (30 Days)
- HSCS 50.6K
- SONN 6.7M
- Earning Date
- HSCS 07-28-2025
- SONN 08-13-2025
- Dividend Yield
- HSCS N/A
- SONN N/A
- EPS Growth
- HSCS N/A
- SONN N/A
- EPS
- HSCS N/A
- SONN N/A
- Revenue
- HSCS N/A
- SONN $1,000,000.00
- Revenue This Year
- HSCS N/A
- SONN $5,376.22
- Revenue Next Year
- HSCS N/A
- SONN N/A
- P/E Ratio
- HSCS N/A
- SONN N/A
- Revenue Growth
- HSCS 261.17
- SONN 978.39
- 52 Week Low
- HSCS $2.36
- SONN $1.08
- 52 Week High
- HSCS $5.30
- SONN $10.02
- Technical
- Relative Strength Index (RSI)
- HSCS 46.34
- SONN 71.50
- Support Level
- HSCS $3.63
- SONN $1.10
- Resistance Level
- HSCS $3.92
- SONN $4.40
- Average True Range (ATR)
- HSCS 0.31
- SONN 0.33
- MACD
- HSCS -0.02
- SONN 0.24
- Stochastic Oscillator
- HSCS 8.75
- SONN 62.97
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.